MorphoSys (ETR:MOR) has been given a €91.20 ($112.59) target price by equities research analysts at Bryan, Garnier & Co in a research report issued to clients and investors on Wednesday. The brokerage presently has a “buy” rating on the stock. Bryan, Garnier & Co’s price objective would suggest a potential upside of 6.23% from the company’s previous close.
Several other equities research analysts also recently weighed in on MOR. Goldman Sachs Group set a €80.00 ($98.77) price target on shares of MorphoSys and gave the company a “neutral” rating in a research note on Monday, November 27th. Independent Research set a €93.00 ($114.81) price target on shares of MorphoSys and gave the company a “buy” rating in a research note on Friday, December 1st. Berenberg Bank set a €85.00 ($104.94) price target on shares of MorphoSys and gave the company a “buy” rating in a research note on Thursday, December 7th. JPMorgan Chase & Co. set a €86.00 ($106.17) price target on shares of MorphoSys and gave the company a “buy” rating in a research note on Tuesday, December 12th. Finally, HSBC set a €64.00 ($79.01) price target on shares of MorphoSys and gave the company a “sell” rating in a research note on Friday, January 19th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of €83.75 ($103.39).
Shares of MorphoSys (ETR MOR) opened at €85.85 ($105.99) on Wednesday. MorphoSys has a 52 week low of €49.63 ($61.27) and a 52 week high of €87.40 ($107.90). The firm has a market cap of $2,550.00 and a price-to-earnings ratio of -29.10.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.